×
About 445 results

Interactions between cannabidiol and commonly used antiepilepti...
https://doi.org/10.1111/epi.13852
Epilepsia Gaston TE, Bebin EM et. al.

Aug 7th, 2017 - To identify potential pharmacokinetic interactions between the pharmaceutical formulation of cannabidiol (CBD; Epidiolex) and the commonly used antiepileptic drugs (AEDs) through an open-label safety study. Serum levels were monitored to identify interactions between CBD and AEDs. In 39 adults and 42 children, CBD dose was started at 5 mg/kg/day and inc...

Important drug interactions exist between cannabidiol oil and commonly...
https://doi.org/10.1093/rheumatology/kez304
Rheumatology (Oxford, England); Wilson-Morkeh H, Al-Abdulla A et. al.

Jul 31st, 2019 - Important drug interactions exist between cannabidiol oil and commonly prescribed drugs in rheumatology practice.|2019|Wilson-Morkeh H,Al-Abdulla A,Sien L,Mohamed H,Youngstein T,|

Cannabidiol May Boost Blood Levels of Common Seizure Drugs
https://www.medpagetoday.com/neurology/seizures/67107

Aug 7th, 2017 - Cannabidiol (Epidiolex) may alter blood levels of several commonly used antiepileptic drugs in adults and children, according to an open-label study published in Epilepsia. Cannabidiol showed interactions with topiramate (Topamax), rufinamide (Banzel), and clobazam (Onfi) in adult and pediatric patients, reported Tyler Gaston, MD, of the University of A...

Cannabidiol May Negatively Interact With Antiepileptic Drugs
https://www.medscape.com/viewarticle/884459

Aug 18th, 2017 - Cannabidiol, a compound of cannabis that is being investigated as a potential treatment for epilepsy, may negatively interact with commonly used antiepileptic drugs (AEDs), new research suggests. Analysis from an ongoing, open-label compassionate-use study included 42 children and 39 adults given the cannabidiol (CBD) Epidiolex (GW Pharmaceuticals, plc) to aug...

An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5569602/
Cannabis and Cannabinoid Research; Iffland,K.,et al

Jun 1st, 2017 - Introduction: This literature survey aims to extend the comprehensive survey performed by Bergamaschi et al. in 2011 on cannabidiol (CBD) safety and side effects. Apart from updating the literature, this article focuses on clinical studies and CBD potential interactions with other drugs. Results: In general, the often described favorable safety profile of CBD in humans was...

Acute effect of cannabidiol on the activity of various novel antiepileptic drugs in the...
https://doi.org/10.1016/j.neuropharm.2019.107733
Neuropharmacology Socała K, Wyska E et. al.

Aug 5th, 2019 - Cannabidiol and cannabidiol-enriched products have recently attracted much attention as an add-on therapy for epilepsy, especially drug-resistant seizures. It should be, however, remembered that concomitant use of cannabidiol and antiepileptic drugs may pose a risk of interactions between them. For this reason, the aim of our study was to assess the effect of ...

Enzyme induction with antiepileptic drugs: cause for concern?
https://doi.org/10.1111/j.1528-1167.2012.03671.x
Epilepsia Brodie MJ, Mintzer S et. al.

Sep 29th, 2012 - Several commonly prescribed antiepileptic drugs (AEDs)-including phenobarbital, phenytoin, and carbamazepine-stimulate the synthesis of a broad range of monooxygenase and conjugating enzymes. These agents are well known to reduce the duration and action of many lipid- and non-lipid-soluble drugs, including anticoagulants, cytotoxics, analgesics, antiretrovirals, gluc...

Drug interactions with the newer antiepileptic drugs (AEDs)--part 1: pharmacokinetic an...
https://doi.org/10.1007/s40262-013-0087-0
Clinical Pharmacokinetics; Patsalos PN

Jun 21st, 2013 - Since 1989 there has been an exponential introduction of new antiepileptic drugs (AEDs) into clinical practice and these include eslicarbazepine acetate, felbamate, gabapentin, lacosamide, lamotrigine, levetiracetam, oxcarbazepine, perampanel, pregabalin, retigabine (ezogabine), rufinamide, stiripentol, tiagabine, topiramate, vigabatrin and zonisamide; 16 in total. Because often t...

Understanding herb and dietary supplement use in patients with epilepsy.
https://doi.org/10.1111/j.1528-1167.2009.02090.x
Epilepsia Kaiboriboon K, Guevara M et. al.

Jun 3rd, 2009 - To determine the prevalence of herb and dietary supplement use and to provide a comprehensive analysis of factors influencing the use of these products in patients with epilepsy. We performed a cross-sectional study using self-administered questionnaires in a selected group of patients who were receiving care at a tertiary epilepsy center. Logistic regression was used to measure the association...

Assessment of potential drug interactions in patients with epilepsy: impact of age and ...
https://doi.org/10.1212/01.wnl.0000341789.77291.8d
Neurology Gidal BE, French JA et. al.

Feb 4th, 2009 - To understand and quantify the exposure to concomitant medications other than antiepileptic drugs (AEDs) within an age-diverse group of men and women with epilepsy and explore the likelihood of relevant drug interactions as a result. The PharMetrics medical and pharmaceutical claims database was used to extract data for commercially insured adult patients with a diagnosis o...

Effects of lamotrigine and phenytoin on the pharmacokinetics of atorvastatin in healthy...
https://doi.org/10.1111/j.1528-1167.2011.03118.x
Epilepsia Bullman J, Nicholls A et. al.

Jun 4th, 2011 - Statins and antiepileptic drugs (AEDs) are frequently coprescribed to individuals with hypercholesterolemia and new-onset seizures. Statins are metabolized by the cytochrome P450 (CYP) enzyme system. Interactions between statins and agents that undergo CYP metabolism are common. In this study, the effects of two commonly prescribed AEDs, lamotrigine and phenytoin, wi...

Serious adverse effects of cannabidiol (CBD): a review of randomized controlled trials.
https://doi.org/10.1080/17425255.2020.1754793
Expert Opinion on Drug Metabolism & Toxicology; Dos Santos RG, Guimarães FS et. al.

Apr 10th, 2020 - Recent trials using cannabidiol (CBD) have shown that most acute and prolonged adverse effects of CBD are mild to moderate, with rare serious adverse effects (SAEs). This review focused on analyzing SAEs of CBD and their possible relation to drug-drug interactions. We systematically analyzed the SAEs reported in randomized controlled trials (RCTs) involving the administration of oral CBD...

Cannabis use could cause harmful drug interactions
https://www.eurekalert.org/news-releases/937642

Dec 13th, 2021 - SPOKANE, Wash.—Using cannabis alongside other drugs may come with a significant risk of harmful drug-drug interactions, new research by scientists at Washington State University suggests. The researchers looked at cannabinoids—a group of substances found in the cannabis plant—and their major metabolites found in cannabis users’ blood and found that they interfere with two families...

Cannabidiol Elevates Mechanistic Target of Rapamycin Inhibitor Levels in Patients With ...
https://doi.org/10.1016/j.pediatrneurol.2019.11.017
Pediatric Neurology; Ebrahimi-Fakhari D, Agricola KD et. al.

Jan 12th, 2020 - The mechanistic target of rapamycin inhibitors everolimus and sirolimus have activity against multiple manifestations of tuberous sclerosis complex and are approved to treat astrocytomas, angiomyolipomas, lymphangioleiomyomatosis, and epilepsy. Cannabidiol is a novel antiepileptic medication. There is lack of information regarding drug-drug interactions between mechanistic ...

A Phase 1, Open-Label, Pharmacokinetic Trial to Investigate Possible Drug-Drug Interact...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6899822
Clinical Pharmacology in Drug Development; Morrison G, Crockett J et. al.

Feb 23rd, 2019 - GW Pharmaceuticals' formulation of highly purified cannabidiol oral solution is approved in the United States for seizures associated with Lennox-Gastaut and Dravet syndromes in patients aged ≥2 years, for which clobazam, stiripentol, and valproate are commonly used antiepileptic drugs. This open-label, fixed-sequence, drug-drug interaction, healthy volunteer trial i...

Potential anti-epileptic phytoconstituents: An updated review.
https://doi.org/10.1016/j.jep.2020.113565
Journal of Ethnopharmacology; Kaur J, Famta P et. al.

Nov 10th, 2020 - Epilepsy is one of the most commonly occurring non-communicable neurological disorder that affects people of all age groups. Around 50 million people globally are epileptic, with 80% cases in developing countries due to lack of access to treatments determined by high cost and poor availability or it can be defined by the fraction of active epileptic patients who are not appropriately bei...

HIV Transgenic Rats Demonstrate Impaired Sensorimotor Gating But Are Insensitive to Can...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8598295
The International Journal of Neuropsychopharmacology; Roberts BZ, Minassian A et. al.

Aug 3rd, 2021 - HIV-associated neurocognitive disorder (HAND) is commonly observed in persons living with HIV (PWH) and is characterized by cognitive deficits implicating disruptions of fronto-striatal neurocircuitry. Such circuitry is also susceptible to alteration by cannabis and other drugs of abuse. PWH use cannabis at much higher rates than the general population, thus prioritizing the chara...

Cannabidiol May Negatively Interact With Antiepileptic Drugs
https://www.staging.medscape.com/viewarticle/884459

Aug 18th, 2017 - Cannabidiol, a compound of cannabis that is being investigated as a potential treatment for epilepsy, may negatively interact with commonly used antiepileptic drugs (AEDs), new research suggests. Analysis from an ongoing, open-label compassionate-use study included 42 children and 39 adults given the cannabidiol (CBD) Epidiolex (GW Pharmaceuticals, plc) to aug...

Drug-drug interactions between antiepileptics and cannabinoids.
https://doi.org/10.1080/17425255.2019.1605355
Expert Opinion on Drug Metabolism & Toxicology; Miziak B, Walczak A et. al.

Apr 18th, 2019 - About 40% of patients with epilepsy are associated with drug-resistant seizures, therefore there has been a continuous search for novel treatment approaches. In experimental studies, natural and synthetic cannabimimetic compounds alone or combined with antiepileptic drugs (AEDs) have been extensively studied and cannabidiol, a naturally occurring compound, has been involved...

Medical Cannabis for Headache Pain: a Primer for Clinicians.
https://doi.org/10.1007/s11916-021-00974-z 10.1097/ACM.0000000000000265 10.1016/j.jpain.2015.05.002 10.1016/S0304-3959(02)00138-0 10.1093/pm/pnv064 10.1111/head.13281 10.1111/head.13275 10.1111/j.1526-4610.2005.05186.x 10.1177/0333102416663459 10.1097/01.pra.0000454786.97976.96 10.1016/S0304-3959(98)00033-5 10.1111/head.12570 10.1016/j.nbd.2008.01.003 10.1177/1049909115604669 10.1089/can.2017.0046 10.1016/j.drugalcdep.2017.08.010 10.1124/jpet.109.153858 10.1111/j.1526-4610.2012.02170.x 10.1518/001872006778606895 10.1111/j.1476-5381.2011.01238.x 10.1001/jamapsychiatry.2017.0724 10.1016/s0014-2999(02)01369-9 10.3389/fphar.2018.01259 10.1523/JNEUROSCI.0943-13.2013 10.1016/j.neuropharm.2016.03.007 10.1038/sj.npp.1301246 10.1377/hlthaff.2018.05266 10.2174/157340110790909563 10.1002/ert.21577 10.2105/AJPH.2017.303818 10.1186/s12995-016-0115-8 10.1007/s10935-017-0471-x 10.1089/jpm.2011.0113 10.18043/ncm.78.3.168 10.1016/j.ejim.2018.01.004 10.18192/uojm.v8i2.3672 10.1089/can.2016.0024 10.2146/ajhp060471 10.1016/j.sapharm.2015.09.002 10.1016/j.cjca.2018.11.033 10.1002/cbdv.200790152 10.1001/jama.2017.11909 10.2174/138955706776073466 10.17226/24625 10.2147/TCRM.S1928 10.1038/clpt.2010.318.89:400-407 10.1007/s10194-012-0490-1 10.1089/can.2016.0033 10.1177/2150132720946954 10.1371/journal.pone.0187795 10.1177/0269881117699616 10.1016/j.jamda.2017.07.017 10.1186/s10194-018-0862-2 10.1002/phar.1673 10.1111/epi.16093 10.1186/s42238-019-0013-x 10.12659/AJCR.919545 10.1097/AOG.0000000000002354 10.1111/head.13716 10.1002/hup.2732 10.3389/fphar.2017.00983
Current Pain and Headache Reports; Duarte RA, Dahmer S et. al.

Oct 11th, 2021 - Public acceptance of Cannabis sativa L. (cannabis) as a therapeutic option grows despite lags in both research and clinician familiarity. Cannabis-whether as a medical, recreational, or illicit substance-is and has been commonly used by patients. With ongoing decriminalization efforts, decreased perception of harms, and increased use of cannabis in the treatment of symptoms and disease, it is c...